Liver Cancer: Find A Clinical Trial

For more information on our current clinical trials, click here

Researchers at NewYork-Presbyterian/Columbia have been focusing on outcomes after transplant, disparities in access to care, and novel treatment options for biliary cancers. As described above, our surgeons, interventionalists, and hepatologists are on the cutting edge in areas of transplantation, resection, and management of liver disease. Dr. Siegel is a national leader in hepatobiliary oncology trial development. She also holds an NIH grant to study new biomarkers which to define who may respond best to sorafenib and other targeted therapies. The team works closely with our world-class radiology department, led by Laurence Schwartz, who developed many of the imaging assessment tools which are used internationally to assess responses to therapy. Our group also collaborates closely with our systems biology group to assess genomic signatures for specific subtypes of patients with hepatocellular carcinoma. These new imaging technologies and genetic information will then enable earlier prediction of patients who are responding to therapy, and help to target specific drugs to patients who will best respond to them.

The liver program is backed by a terrific basic science team led by Dr. Robert Schwabe, who studies inflammatory pathways which lead to scarring in liver, identifying new therapeutic areas to explore. In addition, Dr. Regina Santella in Environmental Health has performed groundbreaking work in exploring the relationship between environmental exposures (like aflatoxin) on the development of hepatocellular carcinoma. Finally, our Oncology Chair, Dr. Gary Schwartz, is an invaluable collaborator helping to test new drug combinations in preclinical models. Our group has also been at the forefront in studying the relationship between metabolic syndrome (typically obesity and diabetes) and HCC, which is a growing risk factor for all hepatobiliary cancers worldwide.

Our patients have the opportunity to participate in the widest range of clinical trials offered only at comprehensive medical institutions throughout the country. Because of the breadth of our hepatobiliary program, we can provide patients with the widest variety of treatment approaches with a coordinated approach. In every area, we have national and international leaders committed to providing not only the best care, but also the most compassionate care available.